Genmab 2023 Financial Guidance Update; Q3 Net Profit DKK 2,129M Vs DDD 2,582M YoY; Expects Its 2023 Revenue To Be In The Range Of DKK 15,900M - DKK 16,500M, An Increase To The Previous Guidance Of DKK 15,500M – DKK 16,500M
Portfolio Pulse from Benzinga Newsdesk
Genmab has updated its 2023 financial guidance, expecting its revenue to be in the range of DKK 15,900M - DKK 16,500M, an increase from the previous guidance of DKK 15,500M – DKK 16,500M. The company's Q3 net profit was DKK 2,129M, down from DKK 2,582M YoY.
November 07, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Genmab has raised its 2023 revenue guidance, indicating a positive outlook for the company. However, a decrease in Q3 net profit YoY may concern investors.
The raised revenue guidance for 2023 indicates that Genmab expects stronger performance in the future, which could positively impact the stock. However, the decrease in Q3 net profit compared to the previous year might raise concerns among investors, potentially offsetting the positive impact of the raised guidance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100